MCL1

Induced myeloid leukemia cell differentiation protein Mcl-1

325,874 patent compounds predicted against MCL1, 202,262 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gossypol (SCHEMBL3939)	1.00	12/20
SCHEMBL78479	0.44	9/20
Diflunisal (SCHEMBL4337)	0.53	8/20
SCHEMBL67766	0.53	8/20
SCHEMBL66378	0.45	8/20
Umbelliferone (SCHEMBL22018)	1.00	7/20
SCHEMBL23277	0.72	7/20
SCHEMBL78583	0.55	7/20
SCHEMBL78662	0.55	7/20
Athraquinones A (SCHEMBL18614)	1.00	6/20
Esculetin (SCHEMBL24641)	1.00	6/20
Fraxetin (SCHEMBL43472)	1.00	6/20
SCHEMBL84570	0.50	6/20
SCHEMBL70164	0.66	5/20
Mesalamine (SCHEMBL31297)	0.65	5/20
Purpurin (SCHEMBL33871)	0.63	5/20
Psoralen (SCHEMBL17835)	0.55	5/20
SCHEMBL63131	0.34	5/20
Coumarin (SCHEMBL6252)	1.00	4/20
Coumarin (SCHEMBL73511)	0.83	4/20

Germline variants in MCL1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MCL1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MCL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)	PHASE3	RECRUITING
PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL	PHASE3	ACTIVE_NOT_RECRUITING
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia	PHASE2	NOT_YET_RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia	PHASE2	RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML	PHASE1/PHASE2	COMPLETED
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML	PHASE2	UNKNOWN
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML	PHASE1/PHASE2	WITHDRAWN
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)	PHASE2	COMPLETED
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia	PHASE1/PHASE2	COMPLETED
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	WITHDRAWN
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML	PHASE1	RECRUITING
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome	PHASE1	COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission	nan	RECRUITING
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML	nan	RECRUITING
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis	nan	UNKNOWN
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Don't Eat me Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MCL1 binder may also engage these)

Protein	Name	Similarity
Q7YRZ9	—	1.000	Q7YRZ9 →
Q8HYS5	—	1.000	Q8HYS5 →
Q9Z1P3	—	1.000	Q9Z1P3 →
P97287	—	1.000	P97287 →
Q17QK1	—	0.992	Q17QK1 →
P60571	—	0.992	P60571 →
Q5BIR3	—	0.991	Q5BIR3 →
Q8TBC3	—	0.990	Q8TBC3 →
F5HB62	—	0.990	F5HB62 →
G5EGA3	—	0.990	G5EGA3 →
Q99PI5	—	0.990	Q99PI5 →
P19091	—	0.989	P19091 →
O46080	—	0.989	O46080 →
Q2PFD7	—	0.989	Q2PFD7 →
Q91ZP6	—	0.989	Q91ZP6 →
Q8JZP9	—	0.989	Q8JZP9 →
Q7RTV3	—	0.989	Q7RTV3 →
Q5VVW2	—	0.989	Q5VVW2 →
Q6NN85	—	0.989	Q6NN85 →
Q80WL2	—	0.989	Q80WL2 →
Q96RD6	—	0.989	Q96RD6 →
G5EEC5	—	0.988	G5EEC5 →
A7MB27	—	0.988	A7MB27 →
Q9Z0Y7	—	0.988	Q9Z0Y7 →
Q7ZUL9	—	0.988	Q7ZUL9 →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.988	landscape →
P11299	—	0.988	P11299 →
Q9S7P5	—	0.988	Q9S7P5 →
Q9BQK8	—	0.988	Q9BQK8 →
Q96PX1	—	0.988	Q96PX1 →